CRBN and plasma cell myeloma: Finally, integration of DMS data with available clinical data suggests that functional CRBN hotspots are mutated in multiple myeloma patients relapsing from treatment with lenalidomide and pomalidomide, two CRBN-based molecular glue degraders.